These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 24852069

  • 1. Anti-VEGF therapy in myopic choroidal neovascularization: long-term results.
    Freitas-da-Costa P, Pinheiro-Costa J, Carvalho B, Falcão M, Brandão E, Falcão-Reis F, Carneiro Â.
    Ophthalmologica; 2014; 232(1):57-63. PubMed ID: 24852069
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
    Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y.
    Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
    [Abstract] [Full Text] [Related]

  • 3. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
    Ahn SJ, Park KH, Woo SJ.
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
    [Abstract] [Full Text] [Related]

  • 4. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS, Kim JG, Kim JT, Joe SG.
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [Abstract] [Full Text] [Related]

  • 5. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
    Matsuo M, Honda S, Matsumiya W, Kusuhara S, Tsukahara Y, Negi A.
    Eur J Ophthalmol; 2012 Dec; 22(2):210-5. PubMed ID: 21534251
    [Abstract] [Full Text] [Related]

  • 6. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU, Kim YM, Lee SJ, Byun YJ, Koh HJ.
    Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
    [Abstract] [Full Text] [Related]

  • 7. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
    Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Piñero DP.
    Retina; 2010 May; 30(10):1609-15. PubMed ID: 20856171
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study.
    Pasyechnikova NV, Naumenko VO, Korol AR, Zadorozhnyy OS, Kustryn TB, Henrich PB.
    Ophthalmologica; 2015 May; 233(1):2-7. PubMed ID: 25501802
    [Abstract] [Full Text] [Related]

  • 9. Comparison of visual prognoses between natural course of simple hemorrhage and choroidal neovascularization treated with intravitreal bevacizumab in highly myopic eyes: a 1-year follow-up.
    Goto S, Sayanagi K, Ikuno Y, Jo Y, Gomi F, Nishida K.
    Retina; 2015 Mar; 35(3):429-34. PubMed ID: 25166271
    [Abstract] [Full Text] [Related]

  • 10. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
    Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB.
    Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
    [Abstract] [Full Text] [Related]

  • 11. Myopic choroidal neovascularization.
    Ruiz-Moreno JM, López-Gálvez MI, Donate J, Gomez-Ulla F, García-Arumí J, García-Layana A, Sellés I, Reche J, Montero JA, Pazos B, Zapata MA, Pastor JC.
    Ophthalmology; 2011 Dec; 118(12):2521-3. PubMed ID: 22136676
    [No Abstract] [Full Text] [Related]

  • 12. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [Abstract] [Full Text] [Related]

  • 13. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
    Cohen SY, Nghiem-Buffet S, Grenet T, Dubois L, Ayrault S, Fajnkuchen F, Delahaye-Mazza C, Quentel G, Tadayoni R.
    Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
    [Abstract] [Full Text] [Related]

  • 14. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
    Sabry D, Gad MA, Enam KM.
    Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.
    Ruiz-Moreno JM, Arias L, Montero JA, Carneiro A, Silva R.
    Br J Ophthalmol; 2013 Nov; 97(11):1447-50. PubMed ID: 24026146
    [Abstract] [Full Text] [Related]

  • 16. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
    Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, Bandello F.
    Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
    [Abstract] [Full Text] [Related]

  • 17. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
    Hayashi K, Ohno-Matsui K, Teramukai S, Shimada N, Moriyama M, Hayashi W, Yoshida T, Tokoro T, Mochizuki M.
    Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM, Lai TY, Liu DT, Lam DS.
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [Abstract] [Full Text] [Related]

  • 19. Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization.
    Parravano M, Ricci F, Oddone F, Missiroli F, De Felici C, Varano M.
    Retina; 2014 Oct; 34(10):2053-62. PubMed ID: 24946101
    [Abstract] [Full Text] [Related]

  • 20. Effect of intravitreal ranibizumab injections on aqueous humour concentrations of vascular endothelial growth factor and pigment epithelium-derived factor in patients with myopic choroidal neovascularisation.
    Costagliola C, Semeraro F, dell'Omo R, Romano MR, Russo A, Aceto F, Mastropasqua R, Porcellini A.
    Br J Ophthalmol; 2015 Jul; 99(7):1004-8. PubMed ID: 25770144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.